Recent Discoveries and Developments in RNA and DNA Vaccines
A special issue of Vaccines (ISSN 2076-393X). This special issue belongs to the section "DNA and mRNA Vaccines".
Deadline for manuscript submissions: 8 September 2024 | Viewed by 277
Special Issue Editor
2. Department of Biomedical Sciences, Faculty of Health Sciences, University of Macau, Avenida de Universidade, Taipa, Macau SAR, China
3. Ministry of Education (MoE) Frontiers Science Center for Precision Oncology, University of Macau, Avenida de Universidade, Taipa, Macau SAR, China
Interests: novel therapeutic antibodies development; venom-based peptide & natural biomolecule prototype drugs development; cancer biomarkers & immunotherapy markers discovery for prognostic and therapeutic validation
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
With a long history of humans fighting against disease, scientists developed a biological preparation called a vaccine during the 10th century. A vaccine provides an active acquired immunity to a particular infectious or malignant disease. The effectiveness and safety of vaccines are always a significant concern to humankind; thus, scientists have undertaken considerable efforts and performed many pre-clinical and clinical studies to verify these in the last 60 years. RNA or DNA vaccine discovery and development for preventive and therapeutic applications has evolved rapidly in the previous decade. This Special Issue will focus on the most recent advanced research related to RNA or DNA vaccine discovery and development for preventive and therapeutic applications to fight against infectious or malignant diseases. The safest and most efficient RNA or DNA applications underlining the advantages and disadvantages of current RNA or DNA vaccines will be discussed. Both research (in particular) and review articles proposing novelties or overviews, respectively, are welcome.
Prof. Dr. Hang Fai (Henry) Kwok
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Vaccines is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- RNA vaccine
- DNA vaccine
- prevention
- therapy
- delivery system
- lipid nanoparticles
- infectious diseases
- immune response
- cancer
